Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

Share

July 2020; 7 (4) Clinical/Scientific NotesOpen Access

Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome

Giuseppe Cosentino, Marcello Romano, Margherita Algeri, Filippo Brighina, Enrico Alfonsi, Cristina Tassorelli, Grazia Crescimanno
First published April 1, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000715
Giuseppe Cosentino
From the Department of Brain and Behavioral Sciences (G. Cosentino, C.T.), University of Pavia; Clinical Neurophysiology Unit (G. Cosentino, E.A.), IRCCS Mondino Foundation, Pavia; Neurophysiopathology Department (M.R.), Villa Sofia-Cervello Hospital; Division of Pulmonology (DIBIMIS) (M.A.), Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo; Department of Biomedicine Neuroscience and Advanced Diagnostics (F.B.), University of Palermo; Neurorehabilitation Unit (C.T.), IRCCS Mondino Foundation, Pavia; and Institute for Biomedical Research and Innovation (G. Crescimanno), Italian National Research Council, Palermo; Centre for Respiratory Complications of Neuromuscular Rare Disease (G. Crescimanno), Villa Sofia-Cervello Hospital, Palermo, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcello Romano
From the Department of Brain and Behavioral Sciences (G. Cosentino, C.T.), University of Pavia; Clinical Neurophysiology Unit (G. Cosentino, E.A.), IRCCS Mondino Foundation, Pavia; Neurophysiopathology Department (M.R.), Villa Sofia-Cervello Hospital; Division of Pulmonology (DIBIMIS) (M.A.), Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo; Department of Biomedicine Neuroscience and Advanced Diagnostics (F.B.), University of Palermo; Neurorehabilitation Unit (C.T.), IRCCS Mondino Foundation, Pavia; and Institute for Biomedical Research and Innovation (G. Crescimanno), Italian National Research Council, Palermo; Centre for Respiratory Complications of Neuromuscular Rare Disease (G. Crescimanno), Villa Sofia-Cervello Hospital, Palermo, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margherita Algeri
From the Department of Brain and Behavioral Sciences (G. Cosentino, C.T.), University of Pavia; Clinical Neurophysiology Unit (G. Cosentino, E.A.), IRCCS Mondino Foundation, Pavia; Neurophysiopathology Department (M.R.), Villa Sofia-Cervello Hospital; Division of Pulmonology (DIBIMIS) (M.A.), Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo; Department of Biomedicine Neuroscience and Advanced Diagnostics (F.B.), University of Palermo; Neurorehabilitation Unit (C.T.), IRCCS Mondino Foundation, Pavia; and Institute for Biomedical Research and Innovation (G. Crescimanno), Italian National Research Council, Palermo; Centre for Respiratory Complications of Neuromuscular Rare Disease (G. Crescimanno), Villa Sofia-Cervello Hospital, Palermo, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filippo Brighina
From the Department of Brain and Behavioral Sciences (G. Cosentino, C.T.), University of Pavia; Clinical Neurophysiology Unit (G. Cosentino, E.A.), IRCCS Mondino Foundation, Pavia; Neurophysiopathology Department (M.R.), Villa Sofia-Cervello Hospital; Division of Pulmonology (DIBIMIS) (M.A.), Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo; Department of Biomedicine Neuroscience and Advanced Diagnostics (F.B.), University of Palermo; Neurorehabilitation Unit (C.T.), IRCCS Mondino Foundation, Pavia; and Institute for Biomedical Research and Innovation (G. Crescimanno), Italian National Research Council, Palermo; Centre for Respiratory Complications of Neuromuscular Rare Disease (G. Crescimanno), Villa Sofia-Cervello Hospital, Palermo, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrico Alfonsi
From the Department of Brain and Behavioral Sciences (G. Cosentino, C.T.), University of Pavia; Clinical Neurophysiology Unit (G. Cosentino, E.A.), IRCCS Mondino Foundation, Pavia; Neurophysiopathology Department (M.R.), Villa Sofia-Cervello Hospital; Division of Pulmonology (DIBIMIS) (M.A.), Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo; Department of Biomedicine Neuroscience and Advanced Diagnostics (F.B.), University of Palermo; Neurorehabilitation Unit (C.T.), IRCCS Mondino Foundation, Pavia; and Institute for Biomedical Research and Innovation (G. Crescimanno), Italian National Research Council, Palermo; Centre for Respiratory Complications of Neuromuscular Rare Disease (G. Crescimanno), Villa Sofia-Cervello Hospital, Palermo, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Tassorelli
From the Department of Brain and Behavioral Sciences (G. Cosentino, C.T.), University of Pavia; Clinical Neurophysiology Unit (G. Cosentino, E.A.), IRCCS Mondino Foundation, Pavia; Neurophysiopathology Department (M.R.), Villa Sofia-Cervello Hospital; Division of Pulmonology (DIBIMIS) (M.A.), Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo; Department of Biomedicine Neuroscience and Advanced Diagnostics (F.B.), University of Palermo; Neurorehabilitation Unit (C.T.), IRCCS Mondino Foundation, Pavia; and Institute for Biomedical Research and Innovation (G. Crescimanno), Italian National Research Council, Palermo; Centre for Respiratory Complications of Neuromuscular Rare Disease (G. Crescimanno), Villa Sofia-Cervello Hospital, Palermo, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grazia Crescimanno
From the Department of Brain and Behavioral Sciences (G. Cosentino, C.T.), University of Pavia; Clinical Neurophysiology Unit (G. Cosentino, E.A.), IRCCS Mondino Foundation, Pavia; Neurophysiopathology Department (M.R.), Villa Sofia-Cervello Hospital; Division of Pulmonology (DIBIMIS) (M.A.), Department of Internal Medicine, Villa Sofia-Cervello Hospital, Palermo; Department of Biomedicine Neuroscience and Advanced Diagnostics (F.B.), University of Palermo; Neurorehabilitation Unit (C.T.), IRCCS Mondino Foundation, Pavia; and Institute for Biomedical Research and Innovation (G. Crescimanno), Italian National Research Council, Palermo; Centre for Respiratory Complications of Neuromuscular Rare Disease (G. Crescimanno), Villa Sofia-Cervello Hospital, Palermo, Italy.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome
Giuseppe Cosentino, Marcello Romano, Margherita Algeri, Filippo Brighina, Enrico Alfonsi, Cristina Tassorelli, Grazia Crescimanno
Neurol Neuroimmunol Neuroinflamm Jul 2020, 7 (4) e715; DOI: 10.1212/NXI.0000000000000715

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
513

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Stiff person syndrome (SPS) is a rare neurologic disorder characterized by progressively worsening rigidity and spasms of the axial and limb muscles. Dyspnea has been recently recognized as a common symptom in SPS,1 and life-threatening respiratory crises have been occasionally reported and suspected to be responsible for sudden death in these patients.2,3 The pathophysiologic mechanisms of these respiratory manifestations remain unclear. Some authors have hypothesized that rigidity and/or spasm of the muscles of the trunk could prevent normal rib cage movements and excursion of the diaphragm.1

Here, we report the clinical history of a 55-year-old woman affected by SPS since about 10 years, presenting with crises of severe dyspnea in the past 2 years. The woman also bore several autoimmune comorbidities illustrated in table.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Past or concurrent autoimmune comorbidities experienced by the patient

The clinical onset presented with stiffness of the trunk, with exaggerated lumbar lordosis and neck hyperextension, causing postural instability and progressively worsening difficulties in walking until wheelchair dependence. A few months after onset, diffuse painful muscle spasms, mainly induced by voluntary movements or precipitated by external stimuli, appeared in the proximal and distal muscles of the 4 limbs. Spasms slowly worsened over time, being responsible for repeated episodes of muscle and tendon tears. The clinical picture was completed by progressive urinary retention requiring bladder catheterization, likely due to urethral sphincter spasm,4 myoclonic jerks of the abdominal and lower limb muscles, mainly triggered by the attempt to stand up, moderate dysphagia and, finally, acute respiratory crises. The respiratory crises were triggered by cough, laughter, or activities requiring increased respiratory efforts, and they were characterized by a sudden onset and severe dyspnea with mild desaturation (SpO2 range of 85%–90%) as assessed by pulse oximetry. Neurologic examination was remarkable for hyperreflexia in all 4 limbs and positive bilateral Hoffman signs.

MRI examination of the brain and spinal cord was unremarkable. Paraneoplastic profiles were negative. Laboratory tests revealed positive antibodies against glutamic acid decarboxylase (4.7 U/mL, >1.0 U/mL positive), a common finding in subjects with SPS. The diagnosis of SPS was corroborated by electromyographic evidence of continuous motor unit activity in agonist and antagonist muscles, inconstant 3- to 4-Hz pseudorhythmic myoclonic EMG discharges in the lower limbs, and long-latency reflexes evoked by innocuous sural nerve stimulation in the lower limbs.

The patient was unsuccessfully treated with oral prednisone (0.5–1.5 mg/kg/d), several IV immunoglobulin infusions (400 mg/kg/d ×5 days), and immunosuppressive therapy, initially with azathioprine (up to 3 mg/kg/d) and subsequently with cyclosporine A (up to 4 mg/kg/d). Lately, rituximab (375 mg/m2 IV for 4 doses) was added to the corticosteroid treatment, which induced a complete depletion of CD20+ B-Cells, but no clinical improvement. Oral diazepam (10–15 mg/d) and baclofen (75 mg/d) were used to control muscle spasms, with partial benefit. Diazepam doses were not increased beyond 15 mg because of side effects, including daytime sleepiness and forgetfulness. Over the previous 2 years, respiratory crises occurred with increasing frequency (up to 2 per week) and severity of dyspnea, thus becoming a major concern that often required prompt sanitary interventions and multiple accesses to the emergency department. In many cases, dyspnea crises could be interrupted only with IV administration of diazepam. In the attempt to find an effective alternative therapy for the acute management of respiratory crises, we hospitalized the patients for testing the efficacy and usability of midazolam (5 mg/1 mL concentration) via the nasal route.

Midazolam is a short-acting benzodiazepine (BZD), roughly 1.5–2 times more potent than diazepam. When administered intranasally, midazolam is rapidly absorbed and acts very quickly, with possible superiority over the IV route when considering the time needed to place an IV catheter.5,6 Intranasal midazolam is both effective and well tolerated in the acute treatment of status epilepticus. This BDZ has been approved by the FDA for seizure clusters in May 2019. Recent studies have confirmed its safety profile and support the feasibility of intranasal administration as a potential alternative for the out-of-hospital treatment of seizure emergencies.7 Video 1 shows a representative respiratory crisis observed during hospitalization. The crisis was almost immediately interrupted by the nasal administration of midazolam 2.5 mg (0.5 mL) into each nostril by means of a mucosal atomization device. Immediately after treatment, the patient experienced a mild feeling of drowsiness that resolved within 2 hours, but no other side effects. Systolic and diastolic blood pressure moderately decreased for a few hours after treatment, but the values remained within physiologic limits. The average oxygen saturation levels were maintained within the normal range.

Video 1

A respiratory crisis rapidly treated by intranasal midazolam administration (5 mg/1 mL concentration, 2.5 mg/0.5 mL into each nostril). Note that we observed and treated 4 respiratory crises during hospitalization. All the attacks were preceded by dry cough (not shown in the video) and complemented by stridor. During the respiratory crises, the patient became intensely agitated and was unable to speak. Generalized muscle spasms involving trunk and limb muscles typically accompanied the respiratory symptoms were also rapidly relieved by midazolam administration, which induced a clinical improvement of muscle stiffness for about 2 hours. Apart from tachycardia and tachypnea, she did not exhibit autonomic signs such as diaphoresis, pupil dilation, arterial hypertension, and hyperthermia. Physical auscultation revealed the absence of lung sounds. Written consent for off-label drug use and publication of patient information was acquired.Download Supplementary Video 1 via http://dx.doi.org/10.1212/000715_Video_1

After we assessed safety and efficacy of treatment in 4 different occasions in the hospital setting, we trained the patient's relatives to administer the drug at home. Until now, more than 20 respiratory crises have been effectively and safely treated, with a frequency of about one administration every 2 weeks.

In conclusion, based on our multiple observations in a single case, intranasal midazolam administration appears an easily applicable and rapidly effective alternative treatment for respiratory crises due to spasms of the axial muscles in SPS, especially when an IV route is not available.

Classification of evidence

This is a single observational study without control and provides Class IV evidence.

Study funding

No targeted funding reported.

Disclosure

The authors have no conflicts of interest to declare as regards this study. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table
Table
Table

Footnotes

  • The Article Processing Charge was funded by Fondazione Irecs Mondino.

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • Received January 20, 2020.
  • Accepted in final form March 3, 2020.
  • Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Sexauer W,
    2. Woodford M,
    3. Pack K, et al
    . Dyspnea in patients with stiff-person syndrome. Am J Med Sci 2019;358:268–272.
    OpenUrl
  2. 2.↵
    1. Jachiet V,
    2. Laine L,
    3. Gendre T, et al
    . Acute respiratory failure in a patient with stiff-person syndrome. Neurocrit Care 2016;25:455–457.
    OpenUrl
  3. 3.↵
    1. Qureshi A,
    2. Hennessy M
    . Stiff person syndrome (SPS) complicated by respiratory failure: successful treatment with rituximab. J Neurol 2012;259:180–181.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Dumitrascu OM,
    2. Tsimerinov EI,
    3. Lewis RA
    . Gastrointestinal and urologic sphincter dysfunction in stiff person syndrome. J Clin Neuromuscul Dis 2016;18:92–95.
    OpenUrl
  5. 5.↵
    1. Bancke LL,
    2. Dworak H,
    3. Halvorsen M
    . Pharmacokinetics of USL261, a novel formulation of intranasal midazolam. Poster presentation in American Epilepsy Society. Upsher-Smith Laboratories, Inc.; 2012.
  6. 6.↵
    1. Charalambous M,
    2. Volk HA,
    3. Tipold A, et al
    . Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: a multi-center randomized parallel group clinical study. J Vet Intern Med 2019;33:2709–2717.
    OpenUrl
  7. 7.↵
    1. Kälviäinen R
    . Intranasal therapies for acute seizures. Epilepsy Behav 2015;49:303–306.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Classification of evidence
    • Study funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • Stiff person syndrome
  • Medical care

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology - Neuroimmunology Neuroinflammation: 9 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise